• 1
    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 9607.
    Direct Link:
  • 2
    Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17(Suppl.): S18690.
  • 3
    Rhul CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 719.
  • 4
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 120219.
  • 5
    Ostapowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 17305.
  • 6
    Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 8059.
  • 7
    Suzuki A, Angulo P, St Sauver J, et al. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol 2007; 102: 19129.
    Direct Link:
  • 8
    Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008; 47: 194754.
  • 9
    Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91100.
  • 10
    Ekstedt M, Franzen LE, Holmqvist M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 2009; 44: 36674.
  • 11
    Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005; 3: 12608.
  • 12
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 248697.
  • 13
    Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 3739.
  • 14
    Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 131321.
  • 15
    Skinner HA, Sheu WJ. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol 1982; 43: 115770.
  • 16
    Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R. Alcohol consumption and the prevalence of the Metabolic Syndrome in the US.: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 29549.
  • 17
    Djousse L, Arnett DK, Eckfeldt JH, et al. Alcohol consumption and metabolic syndrome: does the type of beverage matter? Obes Res 2004; 12: 137585.
  • 18
    Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 2004; 140: 2119.
  • 19
    Wannamethee SG, Camargo CA Jr, Manson JE, Willett WC, Rimm EB. Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women. Arch Intern Med 2003; 163: 132936.
  • 20
    Gunji T, Matsuhashi N, Sato H, et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am J Gastroenterol 2009; 104: 218995.
  • 21
    Yamada T, Fukatsu M, Suzuki S, et al. Alcohol drinking may not be a major risk factor for fatty liver in Japanese undergoing a health checkup. Dig Dis Sci 2010; 55: 17682.
  • 22
    Hiramine Y, Imamura Y, Uto H, et al. Alcohol drinking patterns and the risk of fatty liver in Japanese men. J Gastroenterol 2011; 46: 51928.
  • 23
    Moriya A, Iwasaki Y, Ohguchi S, et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 37888.
  • 24
    Hamaguchi M, Kojima T, Ohbora A, et al. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World J Gastroenterol 2012; 18: 15667.
  • 25
    Cotrim HP, Freitas LA, Alves E, et al. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 2009; 21: 96972.
  • 26
    Zein CO, Unalp A, Colvin R, McCullough AJ. Advanced fibrosis in NAFLD is associated with lifetime alcohol use, diabetes, and age but not with lifetime cigarette smoking. Hepatology 2007; 46(Suppl. 1): 739A.
  • 27
    Alkerwi A, Boutsen M, Vaillant M, et al. Alcohol consumption and the prevalence of metabolic syndrome: a meta-analysis of observational studies. Atherosclerosis 2009; 204: 62435.
  • 28
    Gunji T, Matsuhashi N, Sato H, et al. Alcohol consumption is inversely correlated with insulin resistance, independent of metabolic syndrome factors and fatty liver diseases. J Clin Gastroenterol 2011; 45: 80813.
  • 29
    Bell RA, Mayer-Davis EJ, Martin MA, D'Agostino RB Jr, Haffner SM. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study. Diabetes Care 2000; 23: 16306.